NBIO (Nascent Biotech) Research & Development: $0.10 Mil (TTM As of Jun. 2024)


What is Nascent Biotech Research & Development?

Nascent Biotech NBIO +66.67% Research & Development is $0.10 Mil as of Jun. 2024.

Research & Development is the aggregate amount of research and development expenses during the year. Nascent Biotech's Research & Development for the three months ended in Jun. 2024 was $0.02 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was $0.10 Mil.

Nascent Biotech  (OTCPK:NBIO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nascent Biotech Research & Development Related Terms

Nascent Biotech Research & Development Historical Data

* Premium members only.

The historical data trend for Nascent Biotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Biotech Research & Development Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Research & Development
Get a 7-Day Free Trial 0.29 0.32 0.20 0.27 0.11

Nascent Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.05 0.01 0.02

Nascent Biotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.10 Mil mean?
Nascent Biotech (NBIO) has a Research & Development of $0.10 Mil as of Jun. 2024. Research and development expense is the total cost for research and development activities. View historical data on Nascent Biotech and its competitors.
Is Nascent Biotech's Research & Development too high?
Nascent Biotech's current Research & Development is $0.10 Mil.
How does Nascent Biotech's Research & Development compare to BTAX and PXMD?
Nascent Biotech's Research & Development of $0.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nascent Biotech and its competitors. Nascent Biotech's current Research & Development is $0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Biotech stock overvalued right now?
Nascent Biotech (NBIO) has a current Research & Development of $0.10 Mil. The current Research & Development is $0.10 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nascent Biotech (NBIO), the current Research & Development is $0.10 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Biotech Business Description

Address 631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.